Christopher J. Sweeney

Also affiliated with Centre for Cancer Biology

MedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 30 papers. Top paper: “Atezolizumab Treatment of Tumors with High Tumor Mutational Burden from MyPathway, a Multicenter, Open-Label, Phase IIa Multiple Basket Study”.

Atezolizumab Treatment of Tumors with High Tumor Mutational Burden from MyPathway, a Multicenter, Open-Label, Phase IIa Multiple Basket Study

Cancer Discovery(2021)10.1158/2159-8290.cd-21-0450

N/A

3.0DataRank · unranked

101 citations

John D. Hainsworth, Razelle Kurzrock, David R. Spigel, Howard A. Burris, Christopher J. Sweeney +9 more

Accumulation of copy number alterations and clinical progression across advanced prostate cancer

Genome Medicine(2022)10.1186/s13073-022-01080-4

N/A

0.889DataRank · unranked

30 citations

Stefanie Friedrich, Chris Brawley, Larissa Mendes, Marina Parry, Adnan Ali +28 more

Transcriptional profiling of primary prostate tumor in metastatic hormone-sensitive prostate cancer and association with clinical outcomes: correlative analysis of the E3805 CHAARTED trial

Annals of Oncology(2021)10.1016/j.annonc.2021.06.003

N/A

0.654DataRank · unranked

77 citations

Hsin-Chieh Huang, V. Wang, Yu‐Hui Chen, Felix Y. Feng, Robert B. Den +11 more

Transcriptomic Analysis of Localized High-risk Prostate Cancer Improves Prognostication and Identifies Benefit from Adding Docetaxel to Definitive Radiotherapy with Androgen Suppression in the NRG Oncology/RTOG 0521 Phase 3 Trial

European Urology Oncology(2025)10.1016/j.euo.2025.04.009

N/A

0.214DataRank · unranked

3 citations

James A. Proudfoot, Elai Davicioni, Yang Liu, Daniel E. Spratt, Jeffry Simko +17 more

Transcriptome classification of PTEN inactivation to predict survival benefit from docetaxel at start of androgen deprivation therapy (ADT) for metastatic prostate cancer (PC): An ancillary study of the STAMPEDE trials.

Journal of Clinical Oncology(2025)10.1200/jco.2025.43.16_suppl.5003

N/A

0.165DataRank · unranked

2 citations

Peter Dutey‐Magni, Marina Parry, Larissa Mendes, Ashwin Sachdeva, J. Proudfoot +15 more

EZH2 inhibition activates a dsRNA–STING–interferon stress axis that potentiates response to PD-1 checkpoint blockade in prostate cancer

Nature Cancer(2021)10.1038/s43018-021-00185-w

N/A

0DataRank · unranked

241 citations

Anjali V. Sheahan, Deborah L. Burkhart, Sylvan C. Baca, Nadia Boufaied, Yin Liu +32 more

Outcomes of older men receiving docetaxel for metastatic hormone-sensitive prostate cancer.

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.6_suppl.82

N/A

0DataRank · unranked

2 citations

M. Dror Michaelson, Richard J. Lee, Joseph A. Greer, Jennifer S. Temel, Christopher J. Sweeney +1 more

Changes in bone turnover markers (BTM) and association with outcomes in patients with metastatic hormone-sensitive prostate cancer (mHSPC) treated with androgen deprivation therapy (ADT) +/- docetaxel (D) in CHAARTED (ECOG-ACRIN E3805).

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.6_suppl.145

N/A

0DataRank · unranked

0 citations

Victoria Wang, Ole‐Petter R. Hamnvik, Yee Ming Cheung, Xiao X. Wei, Praful Ravi +3 more

Association of serum steroid levels with survival in men with metastatic hormone-sensitive prostate cancer (mHSPC) treated with ADT with and without docetaxel on ECOG-ACRIN E3805.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.6_suppl.146

N/A

0DataRank · unranked

0 citations

Victoria Wang, Brett T. Marck, Alvin M. Matsumoto, Christopher J. Sweeney, Elahe A. Mostaghel

Transcriptomic and clinical heterogeneity of metastatic disease timing within metastatic castration-sensitive prostate cancer

Annals of Oncology(2023)10.1016/j.annonc.2023.04.515

N/A

0DataRank · unranked

28 citations

Amol C. Shetty, Alex Hakansson, Kim Van der Eecken, Yang Song, Y. Liu +27 more

IGF-1 axis changes with ADT and docetaxel in metastatic prostate cancer

Endocrine Related Cancer(2023)10.1530/erc-23-0241

N/A

0DataRank · unranked

9 citations

Victoria Wang, Raina N. Fichorova, Bradley A. McGregor, Xiao X. Wei, Shehzad Basaria +2 more

Pharmacological NF‐κB inhibition decreases cisplatin chemoresistance in muscle‐invasive bladder cancer and reduces cisplatin‐induced toxicities.

Molecular Oncology(2023)10.1002/1878-0261.13504

N/A

0DataRank · unranked

10 citations

Christine Levesque, Daniella Bianchi‐Frias, Payel Chatterjee, Hung‐Ming Lam, Carlos Santos +20 more

Basal-luminal subtyping of localized high-risk prostate cancer and benefit of adding docetaxel to definitive radiotherapy with androgen suppression in the NRG Oncology/RTOG 0521 phase III trial.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.5094

N/A

0DataRank · unranked

3 citations

James A. Proudfoot, Elai Davicioni, Yang Liu, Daniel E. Spratt, Felix Y. Feng +15 more

Patient reported quality of life (QOL) and survival outcomes: Analysis of ECOG-ACRIN E3805 chemohormonal androgen ablation randomized trial (CHAARTED) in prostate cancer (PCa).

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.5014

N/A

0DataRank · unranked

0 citations

Xiangying Chu, David F. Jarrard, Michael A. Carducci, Robert S. DiPaola, Lynne I. Wagner +4 more

Randomized Phase II Study Evaluating the Addition of Pembrolizumab to Radium-223 in Metastatic Castration-resistant Prostate Cancer

Cancer Immunology Research(2024)10.1158/2326-6066.cir-22-0306

N/A

0DataRank · unranked

36 citations

Lucia Kwak, Alexander Cheung, Kathryn M. Allaire, Jaqueline Marquez, David D. Yang +21 more

Radiographic Progression-Free Survival and Clinical Progression-Free Survival as Potential Surrogates for Overall Survival in Men With Metastatic Hormone-Sensitive Prostate Cancer

Journal of Clinical Oncology(2024)10.1200/jco.23.01535

N/A

0DataRank · unranked

29 citations

Akash Roy, Larysa Rydzewska, Siyuan Guo, Peter J. Godolphin, Maha Hussain +15 more

Molecular Hallmarks of Prostate-specific Membrane Antigen in Treatment-naïve Prostate Cancer

European Urology(2024)10.1016/j.eururo.2024.09.005

N/A

0DataRank · unranked

14 citations

Raag Agrawal, Nicholas K. Wang, Ida Sonni, Eric V. Li, Jaron Arbet +22 more

Patient-reported Quality of Life and Survival Outcomes in Prostate Cancer: Analysis of the ECOG-ACRIN E3805 Chemohormonal Androgen Ablation Randomized Trial (CHAARTED)

European Urology Oncology(2024)10.1016/j.euo.2024.04.010

N/A

0DataRank · unranked

8 citations

Xiangying Chu, David F. Jarrard, Michael A. Carducci, Robert S. DiPaola, Lynn I. Wagner +4 more

Survival of men with metastatic hormone-sensitive prostate cancer and adrenal-permissive HSD3B1 inheritance

Journal of Clinical Investigation(2024)10.1172/jci183583

N/A

0DataRank · unranked

7 citations

Robert Diaz, Hui‐Ming Lin, Evan Roberts, Lisa G. Horvath, Andrew Martin +7 more

1615P A new prognostic model of overall survival (OS) in patients (pts) with metastatic hormone sensitive prostate cancer (mHSPC)

Annals of Oncology(2024)10.1016/j.annonc.2024.08.1696

N/A

0DataRank · unranked

0 citations

Bingcheng Luo, Shuo Guo, Larysa Rydzewska, Peter J. Godolphin, M.K. Parmar +6 more

Association of serum steroids with survival in metastatic hormone-sensitive prostate cancer

Endocrine Related Cancer(2024)10.1530/erc-24-0140

N/A

0DataRank · unranked

0 citations

Victoria Wang, Brett T. Marck, Nima Sharifi, Alvin M. Matsumoto, Christopher J. Sweeney +1 more

Tumor transcriptome-wide expression classifiers predict treatment sensitivity in advanced prostate cancers

Cell(2025)10.1016/j.cell.2025.07.042

N/A

0DataRank · unranked

24 citations

Peter Dutey‐Magni, Marina Parry, Larissa Mendes, Ashwin Sachdeva, James A. Proudfoot +42 more

A Computational Pathology Model to Predict Docetaxel Benefit in Localized High-Risk and Metastatic Prostate Cancer

Clinical Cancer Research(2025)10.1158/1078-0432.ccr-25-3327

N/A

0DataRank · unranked

2 citations

Naoto Tokuyama, Kamal Hammouda, Tilak Pathak, Tuomas Mirtti, Pingfu Fu +15 more

Genetic Drivers of Quality of Life in Prostate Cancer: An Evaluation of Genetic Polymorphisms and Patient-reported Outcomes in the E3805 CHAARTED trial

European Urology Oncology(2025)10.1016/j.euo.2025.04.003

N/A

0DataRank · unranked

1 citations

Xiangying Chu, Charles J. Ryan, Arjun Gupta, Christopher J. Sweeney, David F. Jarrard +10 more

HSD3B1 Genotype and Clinical Outcomes in Metastatic Castration-Sensitive Prostate Cancer

JAMA Oncology(2020)10.1001/jamaoncol.2019.6496

N/A

0DataRank · unranked

75 citations

Christopher J. Sweeney, Nima Almassi, Chad A. Reichard, C.A. Reddy, Hong Li +9 more

Downregulation of ANPEP Is Associated with Aggressive Prostate Cancer and Poor Disease-specific Outcomes

European Urology Open Science(2025)10.1016/j.euros.2025.12.011

N/A

0DataRank · unranked

0 citations

Purvish Trivedi, Shivanshu Awasthi, Amparo Serna, Jasreman Dhillon, Christopher J. Sweeney +14 more

Impact of baseline serum IL‐8 on metastatic hormone‐sensitive prostate cancer outcomes in the Phase 3 CHAARTED trial (E3805)

The Prostate(2020)10.1002/pros.24074

N/A

0DataRank · unranked

21 citations

Victoria X. Wang, Anis Hamid, Gabriella Santone, Charles G. Drake, Michael A. Carducci +4 more

Luminal B subtype as a predictive biomarker of docetaxel benefit for newly diagnosed metastatic hormone sensitive prostate cancer (mHSPC): A correlative study of E3805 CHAARTED.

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.6_suppl.162

N/A

0DataRank · unranked

18 citations

Victoria Wang, Yu‐Hui Chen, Felix Y. Feng, Robert B. Den, Gerhardt Attard +10 more

Impact of baseline serum IL-8 on metastatic hormone-sensitive (mHSPC) prostate cancer outcomes in the phase III CHAARTED trial (E3805).

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.6_suppl.171

N/A

0DataRank · unranked

1 citations

Victoria Wang, Hidemi S. Yamamoto, Anis Hamid, Charles G. Drake, Michael A. Carducci +4 more

Cabozantinib in Chemotherapy-Pretreated Metastatic Castration-Resistant Prostate Cancer: Results of a Phase II Nonrandomized Expansion Study

UNC Libraries(2020)10.17615/yxdm-6w50

N/A

0DataRank · unranked

0 citations

Christopher J. Sweeney, Frauke Schimmöller, Dana E. Rathkopf, Naomi B. Haas, Celestia S. Higano +16 more